Tanespimycin (17-AAG)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

62 publications

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 287 In stock
USD 97 In stock
USD 297 In stock
USD 797 In stock
USD 1337 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tanespimycin (17-AAG) has been cited by 62 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M2G1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPWT5ZKSzVyPUCuNFAxOzB|IN88US=> NX;OdI9vW0GQR1XS
IST-MEL1 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojUTWM2OD1yLkCwNFQxPyEQvF2= NFzaUIVUSU6JRWK=
NCI-SNU-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHhOJZKSzVyPUCuNFAzODdizszN NYLwUFFPW0GQR1XS
FADU NHvER4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe3WZhbUUN3ME2wMlAxOjB7IN88US=> Mn72V2FPT0WU
C32 NF:xV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GwZWlEPTB;MD6wNFMxPCEQvF2= NFO3[JNUSU6JRWK=
D-566MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PmeWlEPTB;MD6wNFM6KM7:TR?= MlvXV2FPT0WU
LXF-289 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEC0NVkh|ryP M37JNnNCVkeHUh?=
HGC-27 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEC1NUDPxE1? MV7TRW5ITVJ?
RPMI-7951 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ITGlEPTB;MD6wNFcyPyEQvF2= NVXCZ3NwW0GQR1XS
HSC-3 NF20bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XxbWlEPTB;MD6wNFkzQSEQvF2= NGDJ[IdUSU6JRWK=
MIA-PaCa-2 NEW0PZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\iTWM2OD1yLkCxNFA6KM7:TR?= NWrlfHBzW0GQR1XS
KS-1 M4GxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEGzOVUh|ryP M4L1RXNCVkeHUh?=
CAL-51 NV70eIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XlbGlEPTB;MD6wNVQxPSEQvF2= NEPqS4hUSU6JRWK=
MDA-MB-361 NH3tWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXwTWM2OD1yLkCxOFk2KM7:TR?= M4nsV3NCVkeHUh?=
TI-73 NH;ReZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfQd4NKSzVyPUCuNFE4QTZizszN M4C1O3NCVkeHUh?=
AGS NU\XZ5NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjGTWM2OD1yLkCxPVM5KM7:TR?= Ml;OV2FPT0WU
NCI-H460 M174[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vwXmlEPTB;MD6wNVk4PCEQvF2= NIfFUohUSU6JRWK=
A204 M{jWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fpS2lEPTB;MD6wNlI1QSEQvF2= NX;jUXFHW0GQR1XS
CHL-1 M3fmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\td2pSUUN3ME2wMlAzOjVzIN88US=> M3foXXNCVkeHUh?=
DU-4475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEKyOlEh|ryP NUT2e2RsW0GQR1XS
CGTH-W-1 MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\5SmlEPTB;MD6wNlM1QSEQvF2= MYLTRW5ITVJ?
HCC2218 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\VRZp7UUN3ME2wMlAzPDl2IN88US=> M{j4OXNCVkeHUh?=
A2780 NGnVc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DZUmlEPTB;MD6wNlU{OSEQvF2= MnTZV2FPT0WU
NCI-H720 NHfOVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfWbG1FUUN3ME2wMlAzPTR4IN88US=> NGHMcpFUSU6JRWK=
NCI-N87 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEK1PVMh|ryP M3vxWXNCVkeHUh?=
CHP-212 NH3HZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;jcGlEPTB;MD6wNlYzQCEQvF2= NUjjbpUyW0GQR1XS
NCI-H23 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7aTWM2OD1yLkCyOlY2KM7:TR?= Mn\wV2FPT0WU
D-263MG NY\yW|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEK3PFYh|ryP NGXkSYtUSU6JRWK=
ME-180 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEK4PVEh|ryP M2npNnNCVkeHUh?=
SW982 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETKUoNKSzVyPUCuNFI6QTlizszN NYjpXoVwW0GQR1XS
OE19 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXrTWM2OD1yLkCzNFc4KM7:TR?= NFLzc5BUSU6JRWK=
SK-LU-1 NGPyUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvUTWM2OD1yLkCzNFgzKM7:TR?= NEi0SYVUSU6JRWK=
H4 NXfnSoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf0RZpIUUN3ME2wMlA{ODlizszN M4DPcXNCVkeHUh?=
HT-144 M3nFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXVTWM2OD1yLkCzNFk{KM7:TR?= MlHzV2FPT0WU
SK-UT-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEOxO|gh|ryP M2T5c3NCVkeHUh?=
D-336MG M1;qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6yPYFKSzVyPUCuNFM{ODlizszN NY\jWVF[W0GQR1XS
MDA-MB-175-VII NEXHfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTme|VKSzVyPUCuNFM{PTRizszN MnTDV2FPT0WU
GAMG M1qwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PTXmlEPTB;MD6wN|Q{PSEQvF2= MmHsV2FPT0WU
CP50-MEL-B M3LQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEO0OUDPxE1? MkfPV2FPT0WU
OVCAR-5 NVuyUmQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEO0PEDPxE1? M1PZcXNCVkeHUh?=
SK-MES-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LqcGlEPTB;MD6wN|YxPiEQvF2= MXTTRW5ITVJ?
VM-CUB-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMEO2OVch|ryP MmTpV2FPT0WU
WM-115 M{e5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PBd2lEPTB;MD6wN|c3OiEQvF2= NUSxSmN{W0GQR1XS
DSH1 M13adWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEO4NFch|ryP NHXyUWFUSU6JRWK=
Becker NYP1bnNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruTWM2OD1yLkCzPFg2KM7:TR?= M3L2NHNCVkeHUh?=
SW962 M{jvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTuTWM2OD1yLkCzPVQ2KM7:TR?= M1rT[3NCVkeHUh?=
TYK-nu NX\JbYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD1yLkCzPVg2KM7:TR?= MnLJV2FPT0WU
HO-1-N-1 NF3aS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P3emlEPTB;MD6wOFAzOSEQvF2= M3O3[HNCVkeHUh?=
T98G NX65XIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LXcmlEPTB;MD6wOFExOyEQvF2= NHXQOIJUSU6JRWK=
ACN NGX2XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP5Xo52UUN3ME2wMlA1OTZ{IN88US=> MVLTRW5ITVJ?
SW780 MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LtT2lEPTB;MD6wOFIxOyEQvF2= MmXYV2FPT0WU
Detroit562 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L6cWlEPTB;MD6wOFI{QSEQvF2= MXzTRW5ITVJ?
BB49-HNC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S5bGlEPTB;MD6wOFI1OyEQvF2= NVXFWG1MW0GQR1XS
HN M{fHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TERmlEPTB;MD6wOFI4OiEQvF2= M1v0OnNCVkeHUh?=
H9 NULMbmJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLhb4lKSzVyPUCuNFQ{PzFizszN MofyV2FPT0WU
VA-ES-BJ NFfMbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HlcGlEPTB;MD6wOFQ1PyEQvF2= NFOyOWlUSU6JRWK=
MEL-JUSO NH7ZSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMES0O|Uh|ryP NIPuRZFUSU6JRWK=
BT-474 M3HW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32yS2lEPTB;MD6wOFUh|ryP MVTTRW5ITVJ?
CaR-1 NWXCV4xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMES1OFkh|ryP MmPVV2FPT0WU
PSN1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH3O25rUUN3ME2wMlA1PjB|IN88US=> MoHBV2FPT0WU
KYSE-510 NXu1bohFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHwPHJKSzVyPUCuNFQ3PDlizszN M3;ZTHNCVkeHUh?=
KP-4 NELpb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XyfWlEPTB;MD6wOFc2OyEQvF2= M334bnNCVkeHUh?=
KYSE-410 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC0fIJKSzVyPUCuNFQ4PzJizszN MoXzV2FPT0WU
G-402 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zsW2lEPTB;MD6wOFc5QSEQvF2= M4fuXXNCVkeHUh?=
DOK M3T3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OxOWlEPTB;MD6wOFkxOiEQvF2= NHzZfnpUSU6JRWK=
COR-L88 M1\BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfKOYZKSzVyPUCuNFQ6OTJizszN M2e3dnNCVkeHUh?=
SKG-IIIa NUHBcYNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37pVWlEPTB;MD6wOFk5PiEQvF2= M3LCVXNCVkeHUh?=
AN3-CA MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXzTWM2OD1yLkC1JO69VQ>? NVjrNW1FW0GQR1XS
SW48 NEDCeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jxWGlEPTB;MD6wOVA{QSEQvF2= NXTENXNqW0GQR1XS
YKG-1 NVvRWFJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHIeYM1UUN3ME2wMlA2ODdzIN88US=> NFHwdIhUSU6JRWK=
KYSE-150 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrleGdKSzVyPUCuNFUzOzVizszN NXftN28xW0GQR1XS
HuO-3N1 MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq2dGxKSzVyPUCuNFUzOzdizszN MXPTRW5ITVJ?
LB1047-RCC NGrpO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEWyPVYh|ryP MWnTRW5ITVJ?
NCI-H2030 NWn4RXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1yLkC1OFE1KM7:TR?= M4fJXnNCVkeHUh?=
YH-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzLW2ZRUUN3ME2wMlA2PzJ{IN88US=> M3\Z[XNCVkeHUh?=
5637 M1\0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEW3OEDPxE1? M125c3NCVkeHUh?=
LOXIMVI M3HCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEW4O|Ih|ryP Mn;hV2FPT0WU
GT3TKB M1TlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMEW5OFIh|ryP MoPWV2FPT0WU
TCCSUP NEO3W4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXYTWM2OD1yLkC1PVY1KM7:TR?= NVzYfZVrW0GQR1XS
EPLC-272H MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\CUI1kUUN3ME2wMlA3OjB3IN88US=> MVvTRW5ITVJ?
LU-99A NGPFWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HQdWlEPTB;MD6wOlI{PyEQvF2= MkXUV2FPT0WU
NCI-H1755 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3jTWM2OD1yLkC2N|QyKM7:TR?= MmDIV2FPT0WU
KM12 NFS3WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TKSGlEPTB;MD6wOlM1QCEQvF2= MX3TRW5ITVJ?
SF295 NEHZW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vDU2lEPTB;MD6wOlQ2OiEQvF2= NFrPWoFUSU6JRWK=
MZ2-MEL NXOzW5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvqTWM2OD1yLkC2OVU{KM7:TR?= NYL1OndRW0GQR1XS
HEC-1 NHT0bYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjQTWM2OD1yLkC2OVg5KM7:TR?= NIewbo9USU6JRWK=
SW684 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwME[1PVEh|ryP MVjTRW5ITVJ?
SF539 M1vqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwME[2PFEh|ryP MofFV2FPT0WU
GMS-10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwME[2PVkh|ryP MX\TRW5ITVJ?
MV-4-11 M2\Z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;FT4hKSzVyPUCuNFY5ODNizszN NVzqXVNSW0GQR1XS
HT-29 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPtV|JUUUN3ME2wMlA3QTF7IN88US=> MYDTRW5ITVJ?
23132-87 NV20cpdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm4WpNKSzVyPUCuNFY6PSEQvF2= NH[2bFFUSU6JRWK=
SW620 NFr1PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfMdGtKSzVyPUCuNFcxOjZizszN M4HFNnNCVkeHUh?=
HCC1806 NH;jcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vCdGlEPTB;MD6wO|E{OSEQvF2= NV3BNHdiW0GQR1XS
Hs-578-T Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[2UmlEPTB;MD6wO|IxQCEQvF2= M1vqO3NCVkeHUh?=
A2058 NWDDWoY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLCTWM2OD1yLkC3NlI5KM7:TR?= MY\TRW5ITVJ?
MEL-HO MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEeyOVUh|ryP MYXTRW5ITVJ?
HCC2998 NFO3WZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335V2lEPTB;MD6wO|M1PyEQvF2= MnXCV2FPT0WU
HuO9 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTNTWM2OD1yLkC3OVg6KM7:TR?= MWnTRW5ITVJ?
CAL-39 NFXnVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mwVWlEPTB;MD6wO|c3PiEQvF2= NUPLZXRwW0GQR1XS
M14 NHPEZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG2TWM2OD1yLkC3PVE{KM7:TR?= M3rTOHNCVkeHUh?=
BFTC-909 NVnxR|dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr2[mJCUUN3ME2wMlA4QTZ7IN88US=> M1S2PHNCVkeHUh?=
TE-11 NWDhN2VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nVcGlEPTB;MD6wO|k6PiEQvF2= M1;4VnNCVkeHUh?=
TGBC1TKB MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\HXmlEPTB;MD6wPFA1OyEQvF2= M165S3NCVkeHUh?=
L-363 M3vWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEiyNFYh|ryP NHHrWG5USU6JRWK=
A431 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHiTWM2OD1yLkC4NlEh|ryP MXLTRW5ITVJ?
MKN45 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLOWnpKSzVyPUCuNFgzOTlizszN M133N3NCVkeHUh?=
HT-1080 NXjGVmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFfGlEPTB;MD6wPFQ{QSEQvF2= M4LwVHNCVkeHUh?=
OVCAR-8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEi2NlIh|ryP MWfTRW5ITVJ?
LCLC-97TM1 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHxSpdVUUN3ME2wMlA5PzJ6IN88US=> M2HJfXNCVkeHUh?=
M059J NULDb215T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnWPJVJUUN3ME2wMlA6ODJ5IN88US=> M{\ZfXNCVkeHUh?=
SK-MEL-2 NWeybYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHFZlV5UUN3ME2wMlA6ODZizszN MWDTRW5ITVJ?
TE-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJWGlEPTB;MD6wPVIxPCEQvF2= NELEU3JUSU6JRWK=
KYSE-180 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEmyOlIh|ryP NFL5cIhUSU6JRWK=
D-247MG MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jiOGlEPTB;MD6wPVQ2PSEQvF2= M3OwdXNCVkeHUh?=
8-MG-BA NXvGeIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:1bm1RUUN3ME2wMlA6PDd{IN88US=> Mn7iV2FPT0WU
NCI-H1792 M{ewSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjMfplKSzVyPUCuNFk3OThizszN M2rTcXNCVkeHUh?=
MCF7 M4qxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z0[2lEPTB;MD6wPVY4PyEQvF2= NUjRUYRbW0GQR1XS
NCI-H2122 NI[zOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH3PIVUUUN3ME2wMlA6PzR3IN88US=> M4L6RXNCVkeHUh?=
EFO-27 NYn2THUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj2TWM2OD1yLkC5PVk4KM7:TR?= NGPjSZNUSU6JRWK=
LB2241-RCC NGPiVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iyd2lEPTB;MD6xNFA2PCEQvF2= NV:3UlJQW0GQR1XS
SN12C NGHI[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMUCxNFch|ryP NEjlNHNUSU6JRWK=
A498 M2PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf4emVlUUN3ME2wMlExOThizszN NEDhS|JUSU6JRWK=
PANC-03-27 M{jhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMUCyPFYh|ryP NXH5ZlNLW0GQR1XS
NCI-H1581 NGnQZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X0[GlEPTB;MD6xNFI6KM7:TR?= NUn5c4NTW0GQR1XS
U-87-MG NXfuUJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNTWM2OD1yLkGwN|A4KM7:TR?= MX;TRW5ITVJ?
G-401 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[4[VBlUUN3ME2wMlExOzV|IN88US=> NGfRVFBUSU6JRWK=
SiHa MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTLSnJWUUN3ME2wMlExPDh4IN88US=> MnXhV2FPT0WU
U251 NV;JPG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rVUWlEPTB;MD6xNFUzPSEQvF2= Mk\SV2FPT0WU
MMAC-SF MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;pOWlEPTB;MD6xNFU{OSEQvF2= MWLTRW5ITVJ?
BB65-RCC NVPZNGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6zXWlqUUN3ME2wMlExPTV2IN88US=> NV\lXnVIW0GQR1XS
NKM-1 NFHoRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\udm1KSzVyPUCuNVA3PjZizszN M1vCe3NCVkeHUh?=
HD-MY-Z NH3yT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7lTWM2OD1yLkGwPFc{KM7:TR?= Ml7zV2FPT0WU
TGBC11TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj5TWM2OD1yLkGwPVA{KM7:TR?= M4\2TnNCVkeHUh?=
COLO-679 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILNSZNKSzVyPUCuNVEzOTFizszN NIPL[XlUSU6JRWK=
TE-8 M1O4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vpeGlEPTB;MD6xNVI3PCEQvF2= NVTPO|BwW0GQR1XS
SK-MEL-28 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvQNYFKSzVyPUCuNVE{OjFizszN NWHI[2h{W0GQR1XS
SH-4 NV6zR5F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnzWVIzUUN3ME2wMlEyOzV4IN88US=> NWLHOGVoW0GQR1XS
KALS-1 NYHvW2ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMUGzPVMh|ryP NHv0PZdUSU6JRWK=
RKO M3Hj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF20[o1KSzVyPUCuNVE4PjRizszN NGTsZXhUSU6JRWK=
OMC-1 NXPQS3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMUG3PVch|ryP MkXaV2FPT0WU
BT-549 M{HDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom1TWM2OD1yLkGxO|k6KM7:TR?= MVHTRW5ITVJ?
NCI-H28 NI\zUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUG4NVch|ryP NXrmSoFGW0GQR1XS
RXF393 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMUG5PFIh|ryP NWjQZm11W0GQR1XS
COLO-829 NYT1[YVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLnTWM2OD1yLkGyNFA2KM7:TR?= M3PITXNCVkeHUh?=
HMV-II M3:zeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\DWGlEPTB;MD6xNlAzKM7:TR?= MVLTRW5ITVJ?
SW1990 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELaemhKSzVyPUCuNVIyPTdizszN MXnTRW5ITVJ?
NCI-H1437 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXuTWM2OD1yLkGyNVU4KM7:TR?= MW\TRW5ITVJ?
SNB75 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L1dmlEPTB;MD6xNlE3QSEQvF2= NUiySphuW0GQR1XS
EW-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG0TWM2OD1yLkGyOlYyKM7:TR?= MV3TRW5ITVJ?
SAS Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLHOmJQUUN3ME2wMlEzPjlizszN MXrTRW5ITVJ?
NCI-H1666 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWxTWM2OD1yLkGyO|c1KM7:TR?= MWnTRW5ITVJ?
A375 M1j6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMUK3O|gh|ryP MlfEV2FPT0WU
CAMA-1 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNT4lKSzVyPUCuNVI6OjRizszN NXW3OWQ3W0GQR1XS
HuP-T4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXYWW41UUN3ME2wMlEzQTR|IN88US=> NGjDTmpUSU6JRWK=
NCI-H292 NGTrXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;RdFlKSzVyPUCuNVMyOSEQvF2= NXXTXFdQW0GQR1XS
PC-14 NIfNSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTT|ZKSzVyPUCuNVMzOTFizszN M1;2b3NCVkeHUh?=
BPH-1 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXmPItTUUN3ME2wMlE{PDFizszN NIjLSWlUSU6JRWK=
GAK NFTZcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTZTWM2OD1yLkGzOVY4KM7:TR?= MUXTRW5ITVJ?
VMRC-RCZ Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly2TWM2OD1yLkGzO|YzKM7:TR?= M33kSHNCVkeHUh?=
SK-MEL-24 NH25PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7FcIdKSzVyPUCuNVM5PyEQvF2= M4f0SHNCVkeHUh?=
LB831-BLC NYmxOZVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe0VpNKSzVyPUCuNVM5QDNizszN MX\TRW5ITVJ?
NCI-H2452 NVy4Vod1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O3XGlEPTB;MD6xN|k2PiEQvF2= M1nBTHNCVkeHUh?=
RT-112 NFzEXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\mTWM2OD1yLkG0NFM2KM7:TR?= MWnTRW5ITVJ?
GP5d NXfwTWZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMUSxNFQh|ryP NVPOclJWW0GQR1XS
LC-2-ad M4\t[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;0NWlEPTB;MD6xOFEzOSEQvF2= MYXTRW5ITVJ?
MPP-89 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmroTWM2OD1yLkG0NVI2KM7:TR?= M3[zbnNCVkeHUh?=
NUGC-3 NIHSOItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2VZlKSzVyPUCuNVQ1PzhizszN MkDIV2FPT0WU
GI-1 NW\WZXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXR[WdKSzVyPUCuNVQ2PThizszN NUfC[JVnW0GQR1XS
HCC1419 NILqVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;zVGlEPTB;MD6xOFU4PiEQvF2= MleyV2FPT0WU
SW1573 M2S0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELFWG9KSzVyPUCuNVQ4PThizszN M1jD[3NCVkeHUh?=
NCI-H2347 M2i4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3QOY5KSzVyPUCuNVQ5OzlizszN MYrTRW5ITVJ?
Mewo MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\lZoRUUUN3ME2wMlE1QDh7IN88US=> NWTPW|c5W0GQR1XS
639-V MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMUWwNVMh|ryP NHny[INUSU6JRWK=
AsPC-1 NYT3RY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMUWyNlUh|ryP MnO1V2FPT0WU
NCI-H1648 NIjmVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLsRmhKSzVyPUCuNVUzOzJizszN NVrmSIt[W0GQR1XS
786-0 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jnfGlEPTB;MD6xOVM5OSEQvF2= NXfYVWtxW0GQR1XS
ETK-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LZemlEPTB;MD6xOVkh|ryP Ml;5V2FPT0WU
BxPC-3 NULTVI1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfLT4lvUUN3ME2wMlE2QTZ4IN88US=> MYPTRW5ITVJ?
CAL-62 NHvKeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu2ZoNKSzVyPUCuNVYyPjlizszN NVvTXG5TW0GQR1XS
HCC1937 NYTmVZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17wcGlEPTB;MD6xOlI4PSEQvF2= MnPoV2FPT0WU
NCI-H1299 NFXOWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\STWM2OD1yLkG2Nlg2KM7:TR?= MXPTRW5ITVJ?
SW1088 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMU[0NVMh|ryP M{L0UHNCVkeHUh?=
FTC-133 MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jJb2lEPTB;MD6xOlU1KM7:TR?= MnzsV2FPT0WU
OC-314 M3XufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMU[2PUDPxE1? NV;GfVFEW0GQR1XS
SCC-9 NVO5WnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLGVJVkUUN3ME2wMlE3PzF4IN88US=> M13obHNCVkeHUh?=
HT-1376 NEDiUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfSfVlKSzVyPUCuNVY6OzZizszN NVnr[3RXW0GQR1XS
U-2-OS NGPuTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnftTWM2OD1yLkG3NVc{KM7:TR?= MmHxV2FPT0WU
COLO-824 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUeyPVQh|ryP NYjUbGIyW0GQR1XS
BB30-HNC NFLRO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLWTWM2OD1yLkG3N|Mh|ryP NYHoNYVQW0GQR1XS
NCI-H2087 NFXTRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\tbGlEPTB;MD6xO|M3QCEQvF2= MVTTRW5ITVJ?
NCI-H2170 NXvieWppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3adpBKSzVyPUCuNVc2OzZizszN MmrsV2FPT0WU
SK-OV-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInsW|FKSzVyPUCuNVc2PzFizszN MorBV2FPT0WU
MZ7-mel MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonQTWM2OD1yLkG3OlQ6KM7:TR?= NES5dWFUSU6JRWK=
NCI-H650 NFXoWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTvbXFKSzVyPUCuNVc3QDJizszN NHWz[lhUSU6JRWK=
KOSC-2 NVzxTpV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnDOnNWUUN3ME2wMlE4PzN2IN88US=> MlnrV2FPT0WU
SCC-4 M1L3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMUe3O|ch|ryP NH3iPYxUSU6JRWK=
MDA-MB-157 M3frPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vrTGlEPTB;MD6xPFA5OiEQvF2= NV;BNHpUW0GQR1XS
KYSE-520 NIDhZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu5TWM2OD1yLkG4NkDPxE1? M2\mTXNCVkeHUh?=
LK-2 M4HQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMUizNFMh|ryP NGe1[G1USU6JRWK=
KNS-81-FD M2Du[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\USHJKSzVyPUCuNVg{QTRizszN MXXTRW5ITVJ?
IGROV-1 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr6VVdKSzVyPUCuNVg1PDNizszN NGXJfo9USU6JRWK=
DEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[0PWlEPTB;MD6xPFQ2KM7:TR?= M2joUXNCVkeHUh?=
NCI-H1395 NGD1dYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf2eIFKSzVyPUCuNVg3QDJizszN MlToV2FPT0WU
JEG-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v5[GlEPTB;MD6xPFcxPSEQvF2= NEnTfZRUSU6JRWK=
BCPAP NVLJNHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PiVmlEPTB;MD6xPFg4OiEQvF2= NXHMW2Y{W0GQR1XS
CAL-27 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMUmwNlIh|ryP NVXEc4VDW0GQR1XS
RD MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\vTWM2OD1yLkG5NVE{KM7:TR?= NWHhWJZoW0GQR1XS
RVH-421 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy2PYFKSzVyPUCuNVkyOTZizszN M3LTW3NCVkeHUh?=
Capan-2 M37GPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\tTWM2OD1yLkG5NlU3KM7:TR?= MWfTRW5ITVJ?
COLO-680N NVrZe2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDYNJZGUUN3ME2wMlE6OzZ2IN88US=> NETMW2dUSU6JRWK=
NCI-H1650 NFn0XlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO2fYhKSzVyPUCuNlAxPTdizszN MYDTRW5ITVJ?
SBC-5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPueHpKSzVyPUCuNlAyOThizszN NEfqVIZUSU6JRWK=
U031 NVzyVVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DtPWlEPTB;MD6yNFU1PyEQvF2= MmLXV2FPT0WU
S-117 M3vjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH6TWM2OD1yLkKwOVY1KM7:TR?= NWm3WXBQW0GQR1XS
DoTc2-4510 M12w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjTS4NKSzVyPUCuNlA4PjlizszN NX\oV41zW0GQR1XS
AM-38 NXLyPJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjLTWM2OD1yLkKwPFQ5KM7:TR?= MkXQV2FPT0WU
A172 NIfKT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvSWm9KSzVyPUCuNlExOjJizszN MofTV2FPT0WU
HPAF-II NWTmV5lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX4WmlJUUN3ME2wMlIyOjZ2IN88US=> M3Ox[nNCVkeHUh?=
769-P MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTtVnJ2UUN3ME2wMlIyOjhizszN MU\TRW5ITVJ?
MFE-280 NUS0SXg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMkGyPVgh|ryP NEL6OHVUSU6JRWK=
TE-9 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe2WlZKSzVyPUCuNlE4QDZizszN Mnq5V2FPT0WU
C2BBe1 MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETWU4dKSzVyPUCuNlIyQSEQvF2= MlX0V2FPT0WU
EoL-1-cell NHPjfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\WW5lKSzVyPUCuNlIzODNizszN MUTTRW5ITVJ?
G-361 M3rlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X5U2lEPTB;MD6yNlY5OiEQvF2= MorNV2FPT0WU
KYSE-270 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljKTWM2OD1yLkKzNFg1KM7:TR?= MVLTRW5ITVJ?
TK10 NHeySpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTue5QxUUN3ME2wMlI{OTF5IN88US=> MmXZV2FPT0WU
ML-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDuN3JmUUN3ME2wMlI{OTF7IN88US=> Mmf3V2FPT0WU
MHH-ES-1 NVXaO3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMkO2PFEh|ryP MWfTRW5ITVJ?
BHY NUn2fJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL2[Y5KSzVyPUCuNlM3QTFizszN NYf2ZYpnW0GQR1XS
LS-513 M{PofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTsU3RjUUN3ME2wMlI{QTZzIN88US=> MXHTRW5ITVJ?
COLO-678 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrWVnNKSzVyPUCuNlQxPDRizszN NIDucIxUSU6JRWK=
NCI-H747 NH20WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS4TWM2OD1yLkK0NVY6KM7:TR?= M17r[nNCVkeHUh?=
K5 M4nGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjT[phNUUN3ME2wMlI1OzhizszN MX3TRW5ITVJ?
OS-RC-2 NGDoWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\FTms2UUN3ME2wMlI1PTB7IN88US=> M1rlOHNCVkeHUh?=
KINGS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMkS1Nlkh|ryP NG\HVJFUSU6JRWK=
SCC-25 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMkS1OlMh|ryP MXnTRW5ITVJ?
CAPAN-1 NVrlVGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTmUmZuUUN3ME2wMlI1Pzh|IN88US=> MoKyV2FPT0WU
ESS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHoTWM2OD1yLkK0PFA2KM7:TR?= NHK2SGZUSU6JRWK=
TE-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMkW3OUDPxE1? MWPTRW5ITVJ?
LB2518-MEL M2TEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMkW3O|ch|ryP NUHIdJBxW0GQR1XS
COLO-800 M3TzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\McGZKSzVyPUCuNlU5OTJizszN MXjTRW5ITVJ?
LU-134-A NF25[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT4TWM2OD1yLkK2NVM3KM7:TR?= MVjTRW5ITVJ?
NCI-H1155 M2e3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPETWM2OD1yLkK2NVYzKM7:TR?= NG\uTnVUSU6JRWK=
MFM-223 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnxRXB[UUN3ME2wMlI3OzZ|IN88US=> MmfjV2FPT0WU
HTC-C3 NHfWT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTSdm1KSzVyPUCuNlY2ODZizszN NFXuNGRUSU6JRWK=
HCT-116 M4mxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrZZYtKSzVyPUCuNlY2QTlizszN NGf3eVBUSU6JRWK=
Ca-Ski MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojiTWM2OD1yLkK2Olc5KM7:TR?= MWnTRW5ITVJ?
SBC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;4UGlEPTB;MD6yOlc1OiEQvF2= M4fMZnNCVkeHUh?=
NB69 NXj2Vo97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCzTWM2OD1yLkK3NFg4KM7:TR?= MnX0V2FPT0WU
J82 NEDnPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMkeyOlUh|ryP NVnmcplmW0GQR1XS
U-118-MG NF3td2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hv[2lEPTB;MD6yO|U4QSEQvF2= NVvYOlJwW0GQR1XS
NCI-H1355 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrZTWM2OD1yLkK4NFc1KM7:TR?= NHLCU3BUSU6JRWK=
NCI-H1048 M1XPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT3SpNPUUN3ME2wMlI5QTV4IN88US=> NVn3T3l2W0GQR1XS
SW954 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\OTWM2OD1yLkK5NlI4KM7:TR?= Mn;FV2FPT0WU
NMC-G1 NYG4RVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHienlsUUN3ME2wMlI6Ojd5IN88US=> NF[xe29USU6JRWK=
SW1710 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW4TWM2OD1yLkK5OFk1KM7:TR?= MnLrV2FPT0WU
KY821 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2NGlEPTB;MD6yPVg4OiEQvF2= MlnQV2FPT0WU
HCC38 M1;MNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:5eWdKSzVyPUCuN|AxPzhizszN NILwbFlUSU6JRWK=
NCI-SNU-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzKXY1KSzVyPUCuN|A2PCEQvF2= MkTEV2FPT0WU
ES8 NX:wemtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzy[mxrUUN3ME2wMlMxPzh2IN88US=> MlfTV2FPT0WU
COLO-792 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD1yLkOxNlUyKM7:TR?= NY\ScGVzW0GQR1XS
BFTC-905 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwM{G1NlEh|ryP NID0em1USU6JRWK=
ChaGo-K-1 NUPRO4ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjXTWM2OD1yLkOxO|E2KM7:TR?= NV3uRmNUW0GQR1XS
Daoy NXO5V|RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPuWHdKSzVyPUCuN|E4OjNizszN NUK3OIpxW0GQR1XS
SJSA-1 NH;0fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DNSWlEPTB;MD6zNVg1PyEQvF2= Ml:1V2FPT0WU
KNS-62 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnMfnhCUUN3ME2wMlMzODh6IN88US=> MkSyV2FPT0WU
CAKI-1 NXPic|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvUYZKSzVyPUCuN|IyOTFizszN M2X5ZnNCVkeHUh?=
UACC-62 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXUOlZKSzVyPUCuN|IzOjdizszN NVPVO2VjW0GQR1XS
HuCCT1 M33lfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjESIZKSzVyPUCuN|IzQDNizszN M1TNUnNCVkeHUh?=
CTB-1 NEjTWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[1[WlEPTB;MD6zNlc2OyEQvF2= MoLEV2FPT0WU
NTERA-S-cl-D1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nBWmlEPTB;MD6zNlg{PiEQvF2= MV;TRW5ITVJ?
T-24 NVXJc3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwM{OxOVkh|ryP M4TsdHNCVkeHUh?=
KYSE-70 MnnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwM{OyPFMh|ryP NWOwRoJzW0GQR1XS
SW626 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LkfmlEPTB;MD6zN|U{OiEQvF2= NVzi[2U4W0GQR1XS
LB996-RCC M3ToTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPnWVlOUUN3ME2wMlM{PjF7IN88US=> MlzxV2FPT0WU
DMS-273 M1j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwM{O5NVYh|ryP NF7TXJJUSU6JRWK=
SW1783 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPDTWM2OD1yLkOzPVk4KM7:TR?= M{TGPHNCVkeHUh?=
KU812 NWq2WGdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXwTWM2OD1yLkO0NFM5KM7:TR?= MmLPV2FPT0WU
HSC-2 NUi5RpBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF72Xm5KSzVyPUCuN|QxPTNizszN NF3CXI9USU6JRWK=
A3-KAW NUnQW|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuXY1KSzVyPUCuN|QyPjJizszN MV7TRW5ITVJ?
COLO-684 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DxeWlEPTB;MD6zOFUxOSEQvF2= MVXTRW5ITVJ?
NCI-H2405 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvMOlVHUUN3ME2wMlM1PjNzIN88US=> MnrDV2FPT0WU
NCI-H2228 M2rzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwM{WzOVch|ryP MWnTRW5ITVJ?
NB13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;KSWlEPTB;MD6zOlgzQSEQvF2= MV7TRW5ITVJ?
no-11 NGDh[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwM{[5OUDPxE1? NECwOFRUSU6JRWK=
DK-MG M2i2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;rSodTUUN3ME2wMlM4OTh6IN88US=> NGrhbIdUSU6JRWK=
NBsusSR NF21XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnIZpZiUUN3ME2wMlM4Ojh3IN88US=> MX7TRW5ITVJ?
KP-N-YS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\v[WlEPTB;MD6zO|Q3OyEQvF2= M4C3UHNCVkeHUh?=
CFPAC-1 NG\6fFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HQeWlEPTB;MD6zO|UyQCEQvF2= NXLnT4xHW0GQR1XS
KARPAS-45 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fDemlEPTB;MD6zO|g3OiEQvF2= NHH6RmxUSU6JRWK=
NCI-H1793 NUfhZZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLvTWM2OD1yLkO4OVEh|ryP Ml3KV2FPT0WU
HCE-T M{PWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP2NJpKSzVyPUCuN|g3ODNizszN MorPV2FPT0WU
NCI-H520 NWOwVJZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSwd5pVUUN3ME2wMlM5PzB|IN88US=> M333XXNCVkeHUh?=
HCC2157 M3XDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwM{i3PFEh|ryP NHXob3hUSU6JRWK=
EW-18 MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i3dmlEPTB;MD6zPFk1OSEQvF2= NIXwfHNUSU6JRWK=
RO82-W-1 NYfnVopmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:yZ2lEPTB;MD6zPVY6QSEQvF2= M4XqVHNCVkeHUh?=
HuP-T3 NXjWUJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64OZpXUUN3ME2wMlQxOTR|IN88US=> M{\mRnNCVkeHUh?=
PANC-10-05 M1HxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULaV|k{UUN3ME2wMlQyOTdizszN M{PyWXNCVkeHUh?=
NCI-H1703 NFGxd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfQVZFKSzVyPUCuOFE1PDZizszN NVjvZZViW0GQR1XS
TE-10 NWqxUFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvqTWM2OD1yLkSxOFQ4KM7:TR?= M3XKUHNCVkeHUh?=
HOS NFTqcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme1TWM2OD1yLkSxOlgzKM7:TR?= M2DEbXNCVkeHUh?=
LN-405 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPvTWM2OD1yLkSxOlg4KM7:TR?= NV60ZZZ7W0GQR1XS
A427 M2HvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C2XmlEPTB;MD60NVk5OSEQvF2= MXnTRW5ITVJ?
CAL-12T NYrWPJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojHTWM2OD1yLkSyO|gh|ryP MkWwV2FPT0WU
SW756 NWLSeIRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfnTWM2OD1yLkS0NVg{KM7:TR?= M4W5cHNCVkeHUh?=
YAPC NXW2PWRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GzdGlEPTB;MD60OVA5KM7:TR?= NYi5enFGW0GQR1XS
GOTO NVq2NGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwNEWxOkDPxE1? NEfvXVZUSU6JRWK=
C3A M3nUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorhTWM2OD1yLkS1OFM4KM7:TR?= NWTDXGg4W0GQR1XS
UM-UC-3 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwNEW0O{DPxE1? NUfHPWJuW0GQR1XS
NCI-H1573 M{jnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OzU2lEPTB;MD60OVU3QSEQvF2= M13MTXNCVkeHUh?=
LS-411N NUnSUFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrmTWM2OD1yLkS2OVI4KM7:TR?= MmLLV2FPT0WU
COR-L23 M1;kWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XYRWlEPTB;MD60Olc3PCEQvF2= MnX3V2FPT0WU
HCE-4 M{TY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPlNJNEUUN3ME2wMlQ4PDR4IN88US=> MVvTRW5ITVJ?
NCI-H2291 MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNEe4PVYh|ryP Mnz5V2FPT0WU
A101D NYPqXFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Doe2lEPTB;MD60PFA2OyEQvF2= MkfJV2FPT0WU
HT-3 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\vUGZEUUN3ME2wMlQ5OjF5IN88US=> NYi1U5J7W0GQR1XS
HOP-62 M3LlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe5NYVKSzVyPUCuOFk5PjVizszN NGjMbmFUSU6JRWK=
PC-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwNUG1NFch|ryP NWe5UWpUW0GQR1XS
CTV-1 NFW5[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwNUK2Olkh|ryP NXHtc2ZDW0GQR1XS
PANC-08-13 NYnTXIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonXTWM2OD1yLkWzNVc4KM7:TR?= NGfZOYdUSU6JRWK=
CAL-120 NX7TbmpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LKNmlEPTB;MD61N|M6QSEQvF2= NUnDPZpxW0GQR1XS
UMC-11 NFW5fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwNUWyN|Qh|ryP NV\ySXFzW0GQR1XS
MSTO-211H M2i3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfj[XdKSzVyPUCuOVU4PjJizszN MV7TRW5ITVJ?
NCI-H2126 M4XPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNU[4NVUh|ryP NE\qdY9USU6JRWK=
SNU-C2B NIL6dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG5TWM2OD1yLkW3PVc4KM7:TR?= M3rsTnNCVkeHUh?=
DBTRG-05MG NIfmXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT6TWM2OD1yLkW4NFU{KM7:TR?= NXnLbYFTW0GQR1XS
MKN1 NGXqR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPGRYtKSzVyPUCuOVg4QDNizszN NWXCSHhCW0GQR1XS
ES3 M{D5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TQSWlEPTB;MD61PVEzPCEQvF2= MXfTRW5ITVJ?
OVCAR-3 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmThTWM2OD1yLkW5N|QyKM7:TR?= MV7TRW5ITVJ?
ACHN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNkC1Olkh|ryP MUDTRW5ITVJ?
SW872 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS3TWM2OD1yLk[wO|Y{KM7:TR?= MYHTRW5ITVJ?
CP66-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MontTWM2OD1yLk[wPVY6KM7:TR?= NV62bIRiW0GQR1XS
NCI-H661 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3KTWM2OD1yLk[xNVA1KM7:TR?= NIWyOGxUSU6JRWK=
UACC-893 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfxS4pKSzVyPUCuOlM3QDFizszN NIK4WGZUSU6JRWK=
JVM-3 NHvGcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHUc5FIUUN3ME2wMlY{QDB2IN88US=> MonkV2FPT0WU
SF268 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwNkSzOFkh|ryP M3:0NnNCVkeHUh?=
OCI-AML2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljWTWM2OD1yLk[1N|k4KM7:TR?= MljrV2FPT0WU
RPMI-8226 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNk[zNlMh|ryP NV2xdWdQW0GQR1XS
MKN28 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXrTGRKSzVyPUCuOlY3OjRizszN NUfOPVdSW0GQR1XS
MDA-MB-453 NVPJfoNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL0TWM2OD1yLk[3NVgh|ryP NYfwOYtWW0GQR1XS
BV-173 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\JTWM2OD1yLk[4Olc6KM7:TR?= MkPGV2FPT0WU
NCI-H358 M2nabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi3TItpUUN3ME2wMlY5PzJ4IN88US=> MYHTRW5ITVJ?
NCI-H1651 NYewS2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe2XHdKSzVyPUCuO{DPxE1? NELQ[ZBUSU6JRWK=
MDA-MB-415 NIDtSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXQTWM2OD1yLkewPFI6KM7:TR?= NF;a[3NUSU6JRWK=
8305C Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq5bG9KSzVyPUCuO|I1QThizszN M17Vd3NCVkeHUh?=
EFM-19 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[3VVViUUN3ME2wMlc{PjdzIN88US=> NGjlb2dUSU6JRWK=
RERF-LC-MS NEnMfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwN{S2NVMh|ryP MVTTRW5ITVJ?
A388 MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLHUYRKSzVyPUCuO|Y1PjdizszN MmK1V2FPT0WU
GI-ME-N NGjhO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BTWM2OD1yLke3NlM2KM7:TR?= NFTaS3FUSU6JRWK=
IGR-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LNOWlEPTB;MD63PVA1OyEQvF2= NGrRXlZUSU6JRWK=
LNCaP-Clone-FGC MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD0TWM2OD1yLkiwNFA1KM7:TR?= M1zERXNCVkeHUh?=
SK-MEL-3 NXe2XIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwOEG1NFgh|ryP NIDZWo9USU6JRWK=
UACC-257 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwOEKyN|Eh|ryP M1fwcnNCVkeHUh?=
OE33 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTIdXpEUUN3ME2wMlg2OTBzIN88US=> M4Lqb3NCVkeHUh?=
QIMR-WIL NH6wT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LXemlEPTB;MD64OVE1OSEQvF2= NFyyTotUSU6JRWK=
NCI-H2009 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwOEWzNVEh|ryP NV\tbHVIW0GQR1XS
NCI-H522 NIHhNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwOEe3PFMh|ryP MnHiV2FPT0WU
Saos-2 M{fMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLQTWM2OD1yLki3PFcyKM7:TR?= NEC5[5NUSU6JRWK=
NB17 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXRTWM2OD1yLki4NFI2KM7:TR?= MYfTRW5ITVJ?
D-392MG NFew[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOEmzOVYh|ryP M1PwTnNCVkeHUh?=
SHP-77 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i1W2lEPTB;MD65NFQ5PSEQvF2= M2rkOHNCVkeHUh?=
SK-MEL-30 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwOUGxPFUh|ryP MVzTRW5ITVJ?
GCIY Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DremlEPTB;MD65NVg1OyEQvF2= NGXOTo9USU6JRWK=
HCC70 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf2dlZKSzVyPUCuPVIxPTlizszN MWrTRW5ITVJ?
LU-65 M4fDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHwTmRDUUN3ME2wMlkzPTlzIN88US=> NFm4bHNUSU6JRWK=
NCI-H1563 NVHQbWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XGeWlEPTB;MD65OFg3PSEQvF2= MWrTRW5ITVJ?
KURAMOCHI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSydWFlUUN3ME2wMlk2OTl{IN88US=> NWrCeHh[W0GQR1XS
PA-1 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjQZYM6UUN3ME2wMlk2PDJ2IN88US=> NULT[o1MW0GQR1XS
NOS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjQ[ZhxUUN3ME2wMlk4PDh7IN88US=> M4fYdHNCVkeHUh?=
NCI-H69 NFfReHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LFbWlEPTB;MD65O|Y{PCEQvF2= MlTFV2FPT0WU
KYSE-450 NV;GWZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLmXGlHUUN3ME2wMlk5PjJ4IN88US=> NVq1OWw5W0GQR1XS
8505C NFfoc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwOUm5PFIh|ryP MVzTRW5ITVJ?
TGBC24TKB NH3tcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnRU|ZsUUN3ME2xMlAxODh2IN88US=> M4f2bnNCVkeHUh?=
PFSK-1 NU\RNI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMEG0Nlgh|ryP NHy2XHRUSU6JRWK=
EKVX NWGzfWU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGxPHEzUUN3ME2xMlA{OTJzIN88US=> NXXm[mZWW0GQR1XS
RCM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrqcWdPUUN3ME2xMlA2PTB5IN88US=> MXnTRW5ITVJ?
SW900 NET2UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwMEe4N{DPxE1? MlTDV2FPT0WU
D-542MG M3H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTkW2w4UUN3ME2xMlA4QDV3IN88US=> M3X3UXNCVkeHUh?=
SK-PN-DW M3;YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwMUCwOVYh|ryP NEXIVWVUSU6JRWK=
NCI-H727 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwMUCxOVQh|ryP NE\VVXRUSU6JRWK=
SW837 M2rEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OyWWlEPTB;MT6xNFk2PCEQvF2= Ml;PV2FPT0WU
BT-20 M1jHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT3SYNKSzVyPUGuNVEzODRizszN MoDhV2FPT0WU
RH-18 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjFb|BKSzVyPUGuNVMyODNizszN MorhV2FPT0WU
TE-12 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwMUOzN|Mh|ryP MmTaV2FPT0WU
NB10 NEXSNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DMZ2lEPTB;MT6xN|M1PCEQvF2= NHr0[|FUSU6JRWK=
AU565 M{\HT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3tTWM2OD1zLkG1PVc{KM7:TR?= MXzTRW5ITVJ?
OAW-42 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTpeodyUUN3ME2xMlE5OzB4IN88US=> MmLXV2FPT0WU
DJM-1 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3hTWM2OD1zLkG5PFgyKM7:TR?= NWOzN292W0GQR1XS
HH NI\q[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fGOGlEPTB;MT6yN|g{OSEQvF2= NVnvXY1zW0GQR1XS
LAMA-84 NYr5TnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[0UZdKSzVyPUGuNlc{QTRizszN M2jZd3NCVkeHUh?=
KNS-42 NVHJOIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon2TWM2OD1zLkOwNlk3KM7:TR?= MWDTRW5ITVJ?
NCI-H2052 NV70TmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL1bGlKSzVyPUGuN|A2ODdizszN NWjhPHdYW0GQR1XS
MLMA NF7xe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwM{K0NFch|ryP NUnxU5ZiW0GQR1XS
NB12 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXP[mRKSzVyPUGuN|U3OzZizszN M4i2S3NCVkeHUh?=
NCI-H1838 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwM{[zNFYh|ryP NFTtW5pUSU6JRWK=
NCI-H526 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HndWlEPTB;MT6zO|g2OyEQvF2= MWTTRW5ITVJ?
LS-123 NEDse3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjhNJBKSzVyPUGuN|kxQTRizszN M1zUPHNCVkeHUh?=
HDLM-2 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nTfWlEPTB;MT6zPVI4OSEQvF2= M{\CPXNCVkeHUh?=
MC-IXC NVzUR3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFewTndKSzVyPUGuOFI{PzFizszN NHvNco1USU6JRWK=
HCT-15 MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwNEOwOlgh|ryP NHLFNplUSU6JRWK=
NCI-H596 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX30XI04UUN3ME2xMlQ2ODZzIN88US=> NFLmR25USU6JRWK=
ZR-75-30 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNEewPFIh|ryP NWHBWHF4W0GQR1XS
A704 M4rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjqVY9KSzVyPUGuOlY2PjNizszN NF;m[YRUSU6JRWK=
OVCAR-4 NFfz[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlKzTWM2OD1zLk[5OlA4KM7:TR?= NILuWXBUSU6JRWK=
SW1417 NGDpS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwN{K4OFkh|ryP NWTnPIdjW0GQR1XS
CAS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qycmlEPTB;MT63N|k{PiEQvF2= MlzpV2FPT0WU
IST-SL1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DSPWlEPTB;MT63PVc2QSEQvF2= MoDaV2FPT0WU
A253 M2q3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfvN5h3UUN3ME2xMlgzOjN7IN88US=> MnvWV2FPT0WU
EW-16 NUfzS3ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj4PG1nUUN3ME2xMlgzQDd3IN88US=> NHm1[2tUSU6JRWK=
SK-NEP-1 NUTnT4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC1TWM2OD1zLki2PVg5KM7:TR?= MmLrV2FPT0WU
NCI-H226 NXzzW4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwOEmzOVkh|ryP Mmn3V2FPT0WU
HOP-92 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKfGlEPTB;MT65OlA6QSEQvF2= NGK0XXBUSU6JRWK=
NCI-H441 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwMEKzN|ch|ryP NWnZXpNNW0GQR1XS
LU-139 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwMEOxNVQh|ryP MmSzV2FPT0WU
SJRH30 NWD4V29IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH3SpFrUUN3ME2yMlA1OjV|IN88US=> NFjMfWZUSU6JRWK=
MG-63 NVjLPWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPXRlBKSzVyPUKuNVQyOTFizszN M3zTe3NCVkeHUh?=
NH-12 M3OzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jScGlEPTB;Mj6xOVAxPiEQvF2= NFvXZmxUSU6JRWK=
NB7 M1jPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D6N2lEPTB;Mj6xPVY4OyEQvF2= M13qfnNCVkeHUh?=
LB771-HNC NE[xeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QTG9KSzVyPUKuNlA2QTVizszN MoDGV2FPT0WU
HCC1569 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[5TWM2OD1{LkK0OVg{KM7:TR?= MXnTRW5ITVJ?
D-283MED MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLXTWM2OD1{LkK0O|gzKM7:TR?= M3f5OHNCVkeHUh?=
J-RT3-T3-5 NV3aSmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7re4ZKSzVyPUKuNlU{PTFizszN NXrCNJY{W0GQR1XS
ATN-1 M2G0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfPenlKSzVyPUKuN|MxQDJizszN NFXoOpZUSU6JRWK=
HCC1954 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nZS2lEPTB;Mj6zOFQxQCEQvF2= NXP2eIo3W0GQR1XS
SCC-15 NETJZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJwM{mzNVIh|ryP MVvTRW5ITVJ?
COLO-668 M2nNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHUTWM2OD1{LkSzNkDPxE1? NIDWTG1USU6JRWK=
LB373-MEL-D MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLoPVV7UUN3ME2yMlU1Pjd5IN88US=> NGDnOmJUSU6JRWK=
no-10 Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP2TWM2OD1{LkW0PVQ4KM7:TR?= MUjTRW5ITVJ?
HT-1197 M1TSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwNkOxPFgh|ryP NE\FeZZUSU6JRWK=
DU-145 NHGwZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfZ[WFKSzVyPUKuO|kyPjJizszN MnLzV2FPT0WU
SK-N-AS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjOdZNpUUN3ME2yMlg1Pjl{IN88US=> M4PXTnNCVkeHUh?=
MOLT-4 NEjDemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf2SJZKSzVyPUKuPFU{OjJizszN MnvSV2FPT0WU
EW-22 M2r2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwOUK4OFEh|ryP MmLUV2FPT0WU
DB NVG0eYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3uTWM2OD1{Lkm3O|U6KM7:TR?= MlrGV2FPT0WU
HL-60 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\YXXJyUUN3ME2zMlA1Ozd4IN88US=> NGDuWVVUSU6JRWK=
SK-N-DZ NXXSe3Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTUSWRKSzVyPUOuNFUxPzVizszN NGLD[2pUSU6JRWK=
NY MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zsUmlEPTB;Mz6wPFU1OiEQvF2= NFPve4FUSU6JRWK=
T47D MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ntNWlEPTB;Mz6xNFU2QCEQvF2= M3\kbnNCVkeHUh?=
NCI-H2029 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET4dGNKSzVyPUOuNlI1PzdizszN Mlz4V2FPT0WU
KARPAS-299 NHnoeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD1|LkK2NFI4KM7:TR?= MVTTRW5ITVJ?
KM-H2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:1TWM2OD1|LkOwOlgh|ryP NGPuRVFUSU6JRWK=
CHP-134 NFjGcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwNEezPUDPxE1? MV\TRW5ITVJ?
22RV1 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n5O2lEPTB;Mz60PVE3QCEQvF2= Mkj3V2FPT0WU
NB5 NIfUWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vyVGlEPTB;Mz61NFY5QSEQvF2= M4DCPXNCVkeHUh?=
CW-2 NWPtVZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrPTJdKSzVyPUOuOVU{OTRizszN MoXEV2FPT0WU
EFO-21 M{nmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvtTWM2OD1|LkW2PVQh|ryP MnrnV2FPT0WU
HuH-7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGyTWM2OD1|LkW4OFE1KM7:TR?= NF;LRW9USU6JRWK=
ALL-PO NEO0NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD1|Lk[yN|M2KM7:TR?= MkXqV2FPT0WU
EM-2 M17J[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nlbGlEPTB;Mz62PVAyOSEQvF2= Mk[0V2FPT0WU
KLE MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNwN{OwNlkh|ryP MnW1V2FPT0WU
NEC8 NV\j[ZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTNwOUG4NFgh|ryP M1vBcHNCVkeHUh?=
KP-N-YN NVSy[HBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwOUO0O|Yh|ryP NGXHU|FUSU6JRWK=
SK-MEL-1 M1G4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vLPGlEPTB;ND6wN|UyQCEQvF2= Mn;4V2FPT0WU
CAL-54 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGraSplKSzVyPUSuNFU6OSEQvF2= MUHTRW5ITVJ?
MS-1 M{KxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M136WmlEPTB;ND6xOlE2PSEQvF2= MmDYV2FPT0WU
NCI-H209 M1jKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjt[oNKSzVyPUSuNlk6QTlizszN NXjlUGZ{W0GQR1XS
NOMO-1 NWfZ[VVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Oye2lEPTB;ND6zNlE{OSEQvF2= M33ybnNCVkeHUh?=
RPMI-2650 NV34UHlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPwTWM2OD12LkO2N|I4KM7:TR?= NWnOblJQW0GQR1XS
NCI-H810 NFXGSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\tU|JsUUN3ME20MlM6PzN4IN88US=> M2PWRnNCVkeHUh?=
Ca9-22 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrDTWM2OD12LkS1OlkyKM7:TR?= Mn7PV2FPT0WU
ES4 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj5TmZKSzVyPUSuOFcxQTVizszN MXnTRW5ITVJ?
ES6 NELtXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRwNEm2OVch|ryP M2Hk[HNCVkeHUh?=
DMS-114 M4n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LqPGlEPTB;ND61OFY6OSEQvF2= MVnTRW5ITVJ?
ONS-76 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXifGdOUUN3ME20MlU4QTVizszN MXPTRW5ITVJ?
K-562 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXFN2VqUUN3ME20Mlc{QDF2IN88US=> MYfTRW5ITVJ?
MHH-NB-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRwN{W0OlEh|ryP MUnTRW5ITVJ?
Calu-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G5ZWlEPTB;ND63PFU1QCEQvF2= MXrTRW5ITVJ?
HT55 NVvKO2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDsTWM2OD12Lki0OVQ2KM7:TR?= MVfTRW5ITVJ?
SK-N-FI MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;aTWM2OD12Lki1NFA6KM7:TR?= NVfQ[2dMW0GQR1XS
ES1 NXjLeWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwOE[wOVch|ryP Ml3TV2FPT0WU
SF126 NFyySHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwOUOxPFQh|ryP MoLTV2FPT0WU
ES5 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3YTWM2OD13LkGyOFI4KM7:TR?= NV\IU|k5W0GQR1XS
LoVo NHP2eZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTVwMUW4O|Eh|ryP M1HPXHNCVkeHUh?=
SNU-387 M1\hNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTH[3B7UUN3ME21MlMzOzN7IN88US=> MVPTRW5ITVJ?
C8166 NVP2d3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTVwM{[zN|kh|ryP NH[4SItUSU6JRWK=
LS-1034 NILSOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjJfWlKSzVyPUWuOFI{ODdizszN MU\TRW5ITVJ?
GR-ST NY\DclJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKboc{UUN3ME21MlUzOjBzIN88US=> NYHINllyW0GQR1XS
NCI-H1092 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwN{K4OFMh|ryP NGPkWYNUSU6JRWK=
647-V NVHKWmV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PxSmlEPTB;NT63OFcxPiEQvF2= M2PwXnNCVkeHUh?=
EW-13 NELtUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnGPW9KSzVyPUWuO|Y3OjdizszN MnLjV2FPT0WU
KGN MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwMEm5NlEh|ryP MnTHV2FPT0WU
D-423MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwNECyPFQh|ryP M33HZXNCVkeHUh?=
ECC10 NHHGdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTdwMUCxNFEh|ryP MmLqV2FPT0WU
TE-5 M3Tpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTdwNEGyPVgh|ryP M3HLVXNCVkeHUh?=
P12-ICHIKAWA NVLqdWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTdwNEW1NlMh|ryP Mn3lV2FPT0WU
NCI-H82 NX32OIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdwNEW3NFEh|ryP M1nLVnNCVkeHUh?=
NCI-H1993 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnZRVg5UUN3ME23Mlg{ODZ|IN88US=> M{\3N3NCVkeHUh?=
RH-1 NELSU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorOTWM2OD15Lki1NlQ1KM7:TR?= MYTTRW5ITVJ?
SW948 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzifmRMUUN3ME23Mlk3ODR7IN88US=> M1\SSHNCVkeHUh?=
CAL-33 NGjEWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDnbYNOUUN3ME23Mlk6QTN6IN88US=> NFn0TplUSU6JRWK=
U-266 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTrSXY2UUN3ME24MlE2Pzd5IN88US=> NF3a[|RUSU6JRWK=
CAL-72 M3LYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S5ZmlEPTB;OD6yNFMzKM7:TR?= MXTTRW5ITVJ?
SNU-423 NEPhT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nXPGlEPTB;OT6zOlY3PiEQvF2= NXXLTGY4W0GQR1XS
KG-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\PXpgxUUN3ME25MlU5PDV4IN88US=> NWK2VmZtW0GQR1XS
HCC1395 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PiXGlEPTB;OT65NlM2OiEQvF2= NXHURY5ZW0GQR1XS
BE-13 M2XFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFyLki4PVIh|ryP MmP6V2FPT0WU
MKN7 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFyLkm3OlUh|ryP M33hT3NCVkeHUh?=
697 NYDPRW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH6W25KSzVyPUGxMlE1PzJizszN MX3TRW5ITVJ?
LU-135 NVLVN|FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFzLkKzNFch|ryP NHv6eWtUSU6JRWK=
ES7 NYrES2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFzLkOzNVMh|ryP MV7TRW5ITVJ?
SK-HEP-1 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LvPGlEPTB;MUGuO|Y1PiEQvF2= MX;TRW5ITVJ?
BEN M2nUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmeyTWM2OD1zMT64OVEh|ryP M4r4S3NCVkeHUh?=
NCI-H1770 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C3PWlEPTB;MUKuNVI3KM7:TR?= M3TXV3NCVkeHUh?=
SW13 NInXcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLEdI1KSzVyPUGyMlE2PDFizszN NVL0XY5tW0GQR1XS
MZ1-PC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\MTWM2OD1zMj61OFUzKM7:TR?= NEn0emNUSU6JRWK=
Mo-T NFr1ZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\ZS2lEPTB;MUKuO|QzOSEQvF2= Mli2V2FPT0WU
HLE NYjpeJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP3TWM2OD1zMj64NlE2KM7:TR?= NWr4SodYW0GQR1XS
RCC10RGB MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXCTWM2OD1zMz62O|Eh|ryP NFj6bI1USU6JRWK=
COLO-320-HSR MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjnb3BKSzVyPUGzMlc{QDFizszN NFHUcJVUSU6JRWK=
BHT-101 M3r5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\rSGlEPTB;MUOuPFM1PSEQvF2= MU\TRW5ITVJ?
OCUB-M MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W0NmlEPTB;MUSuNVYxOiEQvF2= NFfI[lhUSU6JRWK=
MEG-01 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TLTGlEPTB;MUSuN|cxQCEQvF2= MojwV2FPT0WU
RS4-11 M1ix[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF2Lke0NkDPxE1? NYjBWVd7W0GQR1XS
MN-60 NHjPWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF2Lke4PVQh|ryP NUXLZ4duW0GQR1XS
NCI-H1304 NIDmeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjyeXB1UUN3ME2xOU4xPDJ3IN88US=> NEXjfVlUSU6JRWK=
Ramos-2G6-4C10 NFjQdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33HNGlEPTB;MUWuNFU5OSEQvF2= Mn\LV2FPT0WU
NCI-H2342 NGD4[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP5VoFKSzVyPUG1MlIxPDRizszN MnTsV2FPT0WU
LAN-6 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDn[ZJDUUN3ME2xOU41PDF2IN88US=> M4nCenNCVkeHUh?=
JVM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULwZohlUUN3ME2xOU42PzR6IN88US=> MXTTRW5ITVJ?
P30-OHK NHrR[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTMbVJ4UUN3ME2xOk4xPjF2IN88US=> NIO0OGtUSU6JRWK=
C-33-A MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF4Lk[yNVQh|ryP NFGzcVNUSU6JRWK=
RPMI-8866 NXX3OotFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfjTWM2OD1zNj64OFk3KM7:TR?= MV7TRW5ITVJ?
NCI-H630 NGXrclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjFTWM2OD1zNj64OVM4KM7:TR?= MVrTRW5ITVJ?
KYSE-140 NE\C[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\qTWM2OD1zNz6yNFI5KM7:TR?= NXHhUm9KW0GQR1XS
T84 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzNOpBKSzVyPUG4Mlg3QTVizszN MWrTRW5ITVJ?
KU-19-19 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPyTWM2OD1zOD65OlA5KM7:TR?= M3iy[3NCVkeHUh?=
BALL-1 NETNWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\VTWM2OD1zOT6zN|k6KM7:TR?= MX\TRW5ITVJ?
Calu-6 NVHF[JQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLBZoNKSzVyPUG5MlQ6OiEQvF2= M4W1T3NCVkeHUh?=
EGI-1 M2HIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTXndKSzVyPUG5MlU6QCEQvF2= MV3TRW5ITVJ?
MFH-ino NX\zS5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PrN2lEPTB;MUmuO|Q2PCEQvF2= M2rTXnNCVkeHUh?=
GB-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S3bmlEPTB;MkCuN|U{PSEQvF2= M{LzfnNCVkeHUh?=
NCI-H1693 NYLhbWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7PWm5wUUN3ME2yNE43PTB3IN88US=> M{WwUnNCVkeHUh?=
SW1116 NF\5UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDi[XNKSzVyPUKwMlk{PjJizszN MXLTRW5ITVJ?
H-EMC-SS NFPBPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ{LkC0OUDPxE1? NVrzRXV7W0GQR1XS
D-502MG NEDodIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXveIR2UUN3ME2yNk45OjZzIN88US=> MXHTRW5ITVJ?
IA-LM MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6PIc2UUN3ME2yN{4zPDl|IN88US=> NF;mXIpUSU6JRWK=
SW1463 M3rLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ|Lke5JO69VQ>? NHG2V2dUSU6JRWK=
JAR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULoWWNKUUN3ME2yOE4{Ojl|IN88US=> M17ONnNCVkeHUh?=
HT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXvd29KSzVyPUK0MlQ4PTNizszN M1L6bnNCVkeHUh?=
LCLC-103H M1TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn1TWM2OD1{ND64OFQ6KM7:TR?= MUHTRW5ITVJ?
SNU-449 NEDPPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ2Lki3OFEh|ryP MXPTRW5ITVJ?
KE-37 NF\yTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\jTWM2OD1{NT6wPVI5KM7:TR?= NWHofVJCW0GQR1XS
NCI-H1623 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHvTItKSzVyPUK3MlE{ODNizszN M3jrSnNCVkeHUh?=
MOLT-13 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnNTWM2OD1{Nz6zOVE3KM7:TR?= NGTHPIdUSU6JRWK=
COLO-741 NWTQcmlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDDNXBUUUN3ME2zNU4{OzN|IN88US=> NXvC[FdPW0GQR1XS
NB6 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN{LkK4O|Yh|ryP NFzZbYlUSU6JRWK=
MOLT-16 M2f6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHQTWM2OD1|Mz6wNFU2KM7:TR?= MX\TRW5ITVJ?
IST-MES1 NF23TnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN2LkC1OFEh|ryP M2LwV3NCVkeHUh?=
A4-Fuk NHvhUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Thb2lEPTB;M{WuNFY3KM7:TR?= Mmq2V2FPT0WU
CAL-85-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:yeGhrUUN3ME2zOU4zQDF5IN88US=> NVTKRYxKW0GQR1XS
CCRF-CEM MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXvW4NRUUN3ME2zO{4yPTN4IN88US=> MnK5V2FPT0WU
HAL-01 NX\0Nlg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrTcnJKSzVyPUO4MlQ5QDlizszN NFficYhUSU6JRWK=
HEL M3jTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XFfmlEPTB;NEOuN|QxQSEQvF2= MnW1V2FPT0WU
EW-1 M13ZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTR|LkS3Olgh|ryP MX3TRW5ITVJ?
MDA-MB-231 M{jiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2UJFKSzVyPUS1MlEyQTlizszN MkHsV2FPT0WU
ABC-1 NUS5RmJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTR4Lki1N|gh|ryP NV\zO41[W0GQR1XS
NCI-H446 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT3[4xKSzVyPUS4MlUxPThizszN NHX5emxUSU6JRWK=
MHH-PREB-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTIdotKSzVyPUS5MlYxODdizszN MljlV2FPT0WU
DOHH-2 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR7Lk[2OVYh|ryP MkSwV2FPT0WU
GCT NXPGVZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Swd2lEPTB;NEmuOlk4PiEQvF2= NIXjRXFUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
- Collapse
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Water Insoluble
Ethanol '5 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953
Smiles COC1CC(C)CC2=C(NCC=C)C(=O)C=C(NC(=O)C(=C\C=C/C(OC)C(OC(N)=O)/C(=C/C(C)C1O)C)\C)C2=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Related HSP (HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID